Oppenheimer Cuts Price Target on uniQure (QURE) to $23 Following 4Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Oppenheimer Cuts Price Target on uniQure (QURE) to $23 Following 4Q
April 4, 2016 7:45 AM EDT
AMSTERDAM, the Netherlands, April 4, 2016 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ: QURE), the tables were not included. The corrected release follows:
uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced audited results for the fourth quarter and year ending December 31, 2015, and provided a corporate overview on its pipeline programs and operations.
"Over the past several months, we announced proof-of-concept results from our Phase I/II clinical trials in Sanfilippo B and... More
April 4, 2016 5:01 AM EDT
AMSTERDAM, the Netherlands, April 4, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced audited results for the fourth quarter and year ending December 31, 2015, and provided a corporate overview on its pipeline programs and operations.
"Over the past several months, we announced proof-of-concept results from our Phase I/II clinical trials in Sanfilippo B and hemophilia B. Both studies demonstrated not only encouraging safety and efficacy data, but also validated our proprietary AAV5 technology and insect cell, baculovirus production system in both the brain and the... More
